About Lonza
Lonza is a Healthcare company based in Houston (United States) founded in 2009, and was acquired by Lonza in August 2010. Viral vectors for gene therapy applications are manufactured. It operates on a Managed Services and Professional Services model. Lonza offers products and services including Viral Vectors Manufacturing, Process Development, and cGMP Manufacturing. Its focus areas include Biotechnology and Gene Therapy.
Company details
Lonza is involved in the development, clinical, and commercial manufacturing of viral vectors, including AAV, lentivirus, adenoviral, and oncolytic viruses. Services are provided across the biopharmaceutical sector, focusing on gene therapy applications. Solutions are offered for process development, scalability, and cGMP manufacturing, ensuring purity, potency, and regulatory compliance. Expertise is applied in analytical testing and process optimization to meet industry standards. Operations are conducted in specialized facilities designed to address key challenges in therapy manufacturing.
Products & Services of Lonza
Lonza offers a comprehensive portfolio of products and services, including Viral Vectors Manufacturing, Process Development, and cGMP Manufacturing.
Viral vectors are manufactured for gene therapy applications.
Processes are developed for scalable viral vector production.
cGMP manufacturing is provided for clinical and commercial needs.
Apps and channels of Lonza
its YouTube channel Lonza has 4.15K subscribers and 30 videos.
Videos from Lonza
The most watched videos on Lonza's YouTube channel, Lonza (4.15K subscribers). Click a video to play it here.
More on Lonza.
Investors in Lonza
Lonza has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Lonza.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
CDMO services for pharma, biotech, and specialty ingredients are provided. | 1897 | lonza.com | Basel, Switzerland |
Investor details for Lonza
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Lonza
2 dated milestones of Lonza across 1 years, from founding to its latest funding, stage changes and deals.
- Founded Lonza is founded.
- Exit Acquired by Lonza.
Top companies in Cell Therapy
3 companies that operate in the same segment as Lonza (Cell Therapy) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | 520 | ||
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 233 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Lonza
Lonza was founded in 2009.
Lonza is headquartered in Houston, United States. It is registered at Houston, Texas, United States.
Lonza is involved in the development, clinical, and commercial manufacturing of viral vectors, including AAV, lentivirus, adenoviral, and oncolytic viruses. Services are provided across the biopharmaceutical sector, focusing on gene therapy applications. Solutions are offered for process development, scalability, and cGMP manufacturing, ensuring purity, potency, and regulatory compliance. Expertise is applied in analytical testing and process optimization to meet industry standards. Operations are conducted in specialized facilities designed to address key challenges in therapy manufacturing.
Lonza offers Viral Vectors Manufacturing, Process Development, and cGMP Manufacturing.
Lonza has 1 investor. Key investors include Lonza.
Lonza operates through Lonza.
Yes. Lonza was acquired by Lonza in August 2010.